Expert Interview
Examining Biocryst's BCX9930 (oral Factor D inhibitor) for the treatment in patients with C3 Glomerulopathy
Ticker(s): BCRXInstitution: UPENN
- Associate Professor of Clinical Medicine and the Clinical Director, Glomerular Diseases Program at University of Pennsylvania.
- Currently manages 100 patients with IgAN, 1000 patients with CKD, and 15 patients with C3 glomerulopathy.
- Research focuses on Glomerular diseases, Onconephrology, and kidney biopsy.
Roughly how many patients with C3G do you currently manage?
Added By: c_adminOn a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for BCX9930?
Added By: c_adminWhat benefit, if any would BCX9930 provide over current therapies?
Added By: shanandeWith Phase 1 and 2 being 'in vitro' at what point are patients going to test the benefits of this molucule?
Added By: user9c9f5cf9What is your view on C3 inhibition as a primary treatment option for IgAN vs. other development stage therapies that target APRIL and BAFF inhibition?
Added By: tcv1Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
